PharmaCyte Biotech, Inc.
PMCB
$1.64
-$0.12-6.82%
| 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | 10/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.01M | 1.17M | 1.07M | 1.74M | 1.33M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.11M | 1.27M | 1.17M | 1.87M | 1.41M |
| Operating Income | -1.11M | -1.27M | -1.17M | -1.87M | -1.41M |
| Income Before Tax | -1.47M | 23.42M | 1.35M | -619.50K | 2.79M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.47M | 23.42M | 1.35M | -619.50K | 2.79M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.47M | 23.42M | 1.35M | -619.50K | 2.79M |
| EBIT | -1.11M | -1.27M | -1.17M | -1.87M | -1.41M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.39 | 2.62 | -0.30 | -0.65 | -0.26 |
| Normalized Basic EPS | 0.23 | 0.10 | 0.25 | -0.05 | 0.20 |
| EPS Diluted | -0.39 | 2.18 | -0.30 | -0.65 | -0.26 |
| Normalized Diluted EPS | 0.23 | 0.10 | 0.25 | -0.05 | 0.20 |
| Average Basic Shares Outstanding | 7.64M | 7.87M | 8.35M | 8.61M | 8.77M |
| Average Diluted Shares Outstanding | 7.64M | 7.87M | 8.35M | 8.61M | 8.77M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
